Science Advances:三阴性乳腺癌患者福音,科学家成功恢复了乳腺癌突变蛋白!

2017-09-21 佚名 Medicalxpress

弗吉尼亚理工大学研究所的科学家们成功地确定乳腺癌易感蛋白的完整架构(BRCA1)。这个三维结构提供了恢复BRCA1蛋白的抗癌能力的潜在途径。

弗吉尼亚理工大学研究所的科学家们成功地确定乳腺癌易感蛋白的完整架构(BRCA1)。这个三维结构提供了恢复BRCA1蛋白的抗癌能力的潜在途径。

研究结果发表在本周的《高级科学》杂志中,在报告中,研究人员提出更好地管理三阴性乳腺癌中BRCA1突变蛋白质的新模式,三阴乳腺癌是进阶性的,因为其肿瘤细胞通常缺乏目标受体,抗癌药物效果并不显着。这种疾病严重影响着年轻女性,复发性极强。在每年新增的乳腺癌病例中,有15%属于三阴性乳腺癌。另外,男人也可以有三阴性乳腺癌,但很少见,占不到1%的男性乳腺癌。

“三阴性乳腺癌的治愈率极低,患者整日担心疾病复发,三阴性乳腺癌通常与BRCA1基因突变有关。BRCA1基因编码的蛋白在体内每一个细胞,BRCA1蛋白参与保护DNA,防止肿瘤的生长,但BRCA1突变阻碍其保护细胞的能力。我们希望突变蛋白能够履行他们的职责。”

在研究报告中,研究人员描述了第一个长篇生物复杂的结构性信息,那就是BRCA1的三维结构,并将其命名为BARD1。

通过观察这一结构,他们确定了标志着蛋白质BRCA1被摧毁,并发送修复机制的区域细胞。研究团队称这个地区为自我毁灭的“热点”。“BRCA1突变热点地区呈现的蛋白质更容易受到细胞退化。我们发现,我们可以消除信号标签的BRCA1热点,使蛋白质看起来完全正常,恢复蛋白质对抗癌细胞的能力。”

原始出处:
Yanping Liang, William J. Dearnaley, A. Cameron Varano,et al,Structural analysis of BRCA1 reveals modification hotspot,Science Advances, 20 Sep 2017:Vol. 3, no. 9, e1701386DOI: 10.1126/sciadv.1701386

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2047962, encodeId=f63e204e96223, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Mon Jul 09 23:14:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375687, encodeId=f1ee13e56878d, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sat Sep 23 01:14:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458685, encodeId=e92f1458685c6, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Sep 23 01:14:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571064, encodeId=a6ba15e1064cc, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Sep 23 01:14:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2047962, encodeId=f63e204e96223, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Mon Jul 09 23:14:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375687, encodeId=f1ee13e56878d, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sat Sep 23 01:14:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458685, encodeId=e92f1458685c6, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Sep 23 01:14:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571064, encodeId=a6ba15e1064cc, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Sep 23 01:14:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]
    2017-09-23 jichang
  3. [GetPortalCommentsPageByObjectIdResponse(id=2047962, encodeId=f63e204e96223, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Mon Jul 09 23:14:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375687, encodeId=f1ee13e56878d, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sat Sep 23 01:14:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458685, encodeId=e92f1458685c6, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Sep 23 01:14:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571064, encodeId=a6ba15e1064cc, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Sep 23 01:14:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]
    2017-09-23 xlysu
  4. [GetPortalCommentsPageByObjectIdResponse(id=2047962, encodeId=f63e204e96223, content=<a href='/topic/show?id=12e49e53102' target=_blank style='color:#2F92EE;'>#阴性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97531, encryptionId=12e49e53102, topicName=阴性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Mon Jul 09 23:14:00 CST 2018, time=2018-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1375687, encodeId=f1ee13e56878d, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sat Sep 23 01:14:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1458685, encodeId=e92f1458685c6, content=<a href='/topic/show?id=3ef91982030' target=_blank style='color:#2F92EE;'>#三阴性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19820, encryptionId=3ef91982030, topicName=三阴性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5666112721, createdName=xlysu, createdTime=Sat Sep 23 01:14:00 CST 2017, time=2017-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1571064, encodeId=a6ba15e1064cc, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Sep 23 01:14:00 CST 2017, time=2017-09-23, status=1, ipAttribution=)]

相关资讯

SABCS 2013:三阴性乳腺癌新辅助化疗获益

越来越多的三阴性乳腺癌患者在手术前接受新辅助化疗。大约有三分之一的患者,在新辅助化疗实施后,手术时乳腺组织中没有可识别的癌细胞并且淋巴结没有转移,也就是说这些患者出现病理完全缓解(pCR),并且与那些对新辅助化疗没有很好效果的患者相比癌症复发风险低的多。将化疗药物卡铂和/或者靶向治疗药贝伐珠单抗加入到标准术前化疗中,会使手术过程没有残留癌的三阴性乳腺癌患者的数量增加,这是公布在2013年圣安东尼奥

Nature:同济大学参与发表三阴性乳腺癌全新结果

2014年3月24日,在Nature上发表的一项最新研究中,美国威尔康奈尔医学院、加州大学洛杉矶分校、Dana-Farber 癌症研究所、北卡大学教堂山分校、同济大学、四川农业大学、布里格姆妇女医院和哈佛医学院等研究机构在内的一个研究小组,发表了关于三阴性乳腺癌的最新研究结果,表明内质网跨膜蛋白IRE1的底物XBP1,通过控制低氧诱导因子1α通路,可促进三阴性乳腺癌的发展。

本文的资深作者是威尔康奈尔医学院的Laurie H. Glimcher博士。第一作者是威尔康奈尔医学院的博士后Xi Chen博士。哈佛医学院知名生物信息学家、同济大学生物信息学系教授及***讲座教授刘小乐(X. Shirley Liu)博士、同济大学和四川农业大学唐茜子(Qianzi Tang)博士也参与了这项研究工作。

当面对血管化不足引起的压力因素时,癌细胞能够诱导一系列的适应性反应途径。其中一个这样的适应性途径是未折叠蛋白质(UPR)或内质网(ER)应激反应,这个途径是由ER局部跨膜传感蛋白IRE1及其底物XBP1部分介导。

Cell:三阴性乳腺癌细胞可唆使正常细胞模仿病毒帮助肿瘤扩散并耐药

2017年7月13日,美国爱思唯尔旗下《细胞》正式发表宾夕法尼亚大学、罗格斯大学的研究报告稿,发现为何某些乳腺癌比其他乳腺癌更有浸润性、癌细胞如何诱骗正常细胞像病毒一样释放特殊的RNA帮助肿瘤生长、耐药、转移。